Year Founded
2012
Ownership
Private
Therapeutic Areas
Neurology
Stage
Clinical
Modalities
Gene therapyGene therapy

Alcyone Therapeutics General Information

Developing ThecaFlex DRx System for administration of nusinersen (SPINRAZA), currently in IDE clinical study (PIERRE)

Contact Information

Website
Primary Industry
[ "Biotech" ]
Corporate Office
Lowell, Massachusetts
United States

Drug Pipeline

EPH-101
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 2
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 3
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum

For full access to Alcyone Therapeutics's pipeline data

Book a demo

Key Partnerships

Biogen, Nationwide Children's Hospital, University of Idaho

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

Alcyone Therapeutics Funding

No funding data available

Early Stage VC (Series A)04-Jun-2020$38MCompletedPhase 1
Seed Round12-Feb-2019$8.5MCompletedStartup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more
To view Alcyone Therapeutics's complete valuation and funding history, request access »

Alcyone Therapeutics Investors

RTW Investments
Investor Type: Venture Capital
Holding: Minority